Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study

被引:76
作者
Chua, Terence C. [1 ]
Morris, David L. [1 ]
Saxena, Akshat [1 ]
Esquivel, Jesus [3 ]
Liauw, Winston [2 ]
Doerfer, Joerg [4 ]
Germer, Christoph-Thomas [4 ]
Kerscher, Alexander G. [4 ]
Pelz, Joerg O. W. [4 ]
机构
[1] Univ New S Wales, St George Hosp, Dept Surg, Hepatobiliary & Surg Oncol Unit, Sydney, NSW, Australia
[2] St George Hosp, Dept Med Oncol, Sydney, NSW, Australia
[3] St Agnes Hosp, Dept Surg Oncol, Baltimore, MD USA
[4] Univ Wurzburg, Dept Gen Visceral & Paediat Surg, Wurzburg, Germany
关键词
SURGERY; CANCER; RESECTION; SURVIVAL; METASTASES; MORBIDITY; MORTALITY;
D O I
10.1245/s10434-010-1522-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the role of modern systemic therapies and its role as palliative or curative therapy for patients with colorectal peritoneal carcinomatosis with an emphasis on patient selection with the colorectal Peritoneal Surface Disease Severity Score (PSDSS). From three specialized treatment centers, patients with colorectal peritoneal carcinomatosis were identified between December 1988 to December 2009 to receive best supportive care, standard, or modern systemic therapies. Intent was classified as palliative or curative (if treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy). Patients were stratified according to the PSDSS. Survival was estimated by the Kaplan-Meier method. Palliative and curative treatment achieved a median survival of 9 (95% confidence interval [95% CI] 5.9-12.8) and 38 (95% CI 30.2-45.2) months, respectively (P < 0.001). The type of chemotherapy in the palliative and curative group influenced outcome (P < 0.001, P = 0.011, respectively). In the palliative group, PSDSS I/II had a median survival of 24 (95% CI 15.6-32.6) and PSDSS III/IV had a median survival of 6 (95% CI 4.9-8.0) months (P < 0.001). In the curative group, PSDSS I/II had a median survival of 49 (95% CI 40.0-58.3) and PSDSS III/IV had a median survival of 31 (95% CI 20.4-40.9) months (P = 0.002). Modern systemic therapies were associated with improved outcome in patients with colorectal peritoneal carcinomatosis treated systemically alone or with cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Preoperative evaluation with the PSDSS may improve patient selection and optimize outcomes.
引用
收藏
页码:1560 / 1567
页数:8
相关论文
共 15 条
[1]  
Choi Young Il, 2008, Cancer Res Treat, V40, P33, DOI 10.4143/crt.2008.40.1.33
[2]   Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy [J].
Chua, Terence C. ;
Morris, David L. ;
Esquivel, Jesus .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (05) :1330-1336
[3]   Morbidity and Mortality Outcomes of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy at a Single Tertiary Institution Towards a New Perspective of This Treatment [J].
Chua, Terence C. ;
Saxena, Akshat ;
Schellekens, J. F. ;
Liauw, Winston ;
Yan, Tristan D. ;
Fransi, Sal ;
Zhao, Jing ;
Morris, David L. .
ANNALS OF SURGERY, 2010, 251 (01) :101-106
[4]   Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure? A Systematic Review of Morbidity and Mortality [J].
Chua, Terence C. ;
Yan, Tristan D. ;
Saxena, Akshat ;
Morris, David L. .
ANNALS OF SURGERY, 2009, 249 (06) :900-907
[5]   Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study [J].
Elias, Dominique ;
Gilly, Francois ;
Boutitie, Florent ;
Quenet, Francois ;
Bereder, Jean-Marc ;
Mansvelt, Baudouin ;
Lorimier, Gerard ;
Dube, Pierre ;
Glehen, Olivier .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :63-68
[6]   Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin [J].
Elias, Dominique ;
Lefevre, Jeremie H. ;
Chevalier, Julie ;
Brouquet, Antoine ;
Marchal, Frederic ;
Classe, Jean-Marc ;
Ferron, Gwenael ;
Guilloit, Jean-Marc ;
Meeus, Pierre ;
Goere, Diane ;
Bonastre, Julia .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :681-685
[7]   Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion Versus Systemic Chemotherapy Alone for Colorectal Peritoneal Carcinomatosis [J].
Franko, Jan ;
Ibrahim, Zuhaib ;
Gusani, Niraj J. ;
Holtzman, Matthew P. ;
Bartlett, David L. ;
Zeh, Herbert J., III .
CANCER, 2010, 116 (16) :3756-3762
[8]   Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study [J].
Glehen, O ;
Kwiatkowski, F ;
Sugarbaker, PH ;
Elias, D ;
Levine, EA ;
De Simone, M ;
Barone, R ;
Yonemura, Y ;
Cavaliere, F ;
Quenet, F ;
Gutman, M ;
Tentes, AAK ;
Lorimier, G ;
Bernard, JL ;
Bereder, JM ;
Porcheron, J ;
Gomez-Portilla, A ;
Shen, P ;
Deraco, M ;
Rat, P ;
Gilly, FN .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3284-3292
[9]  
JOERG OWP, 2009, J SURG ONCOL, V99, P9
[10]   Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer: A Panacea or Just an Obstacle Course for the Patient? [J].
Khatri, Vijay P. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :5-7